Posted by Michael Wonder on 28 Feb 2024
AB Science announces that Health Canada has issued a notice of non-compliance-withdrawal for masitinib in ALS
26 February 2024 - AB Science today announces that Health Canada has issued a notice of non-compliance-withdrawal regarding its new drug submission for masitinib in the treatment of amyotrophic lateral sclerosis.
Health Canada stated that a request for reconsideration can be filed within 30 days of receiving the notice of non-compliance-withdrawal.
